Multiple Myeloma News & Features
Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials
[Oncotargets and Therapy] This research examines the efficacy and safety of bortezomib-based vs non-bortezomib-based post-transplantation therapy in patients with multiple myeloma.
Researchers have found that spending more leisure time sitting was associated with an increased risk for developing cancer in women.
Patients with relapsed or refractory myeloma experience the most benefit from panobinostat plus bortezomib and dexamethasone.
Researchers have reported safely using immune cells grown from patients' own bone marrow to treat multiple myeloma, according to clinical trial data.
Addition of elotuzumab significantly reduced risk of disease progression in relapsed or refractory multiple myeloma.
Multiple Myeloma Clinical Trials
- In breast cancer survivors, lidocaine may relieve pain during intercourse
- Likelihood of lung cancer screening update
- Generic meds may boost survival in some early breast cancers
- Aromatase inhibitors substantially reduce risk of death in ER-positive breast cancer
- Activated T cell therapy developed for advanced melanoma
- Avocados may hold the answer to beating leukemia
- Cardio-oncology services may improve patient care if more widely available
- Managing oral oncology/hematology treatments in your practice
- Universal health literacy precautions recommended to assist patient understanding
- Acrylamide in Food and Cancer Risk (Fact Sheet)
- Online registry improves clinical research study participation
- Five-day aprepitant versus fosaprepitant in patients receiving cisplatin
- Black men twice as likely to die from prostate cancer compared to white men
- Research findings differentiate prostate cancer tumors into five different types
- Robotic IVC thrombectomy appears successful in patients with kidney cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|